Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2023-12-21 Regulatory Filings
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Zakup dokumentacji dot. projektu innowacyjnego kandydata na lek TRIA-662 - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a formal announcement from the Management Board ("Zarząd") of Pharmena S.A. detailing a significant corporate transaction: the acquisition of full documentation for drug candidate TRIA-662 from its wholly-owned subsidiary, Cortria Corporation, and the subsequent plan to liquidate Cortria. Crucially, it explicitly states the financial impact: impairment charges of PLN 46 million affecting the individual financial statements for 2023. This transaction involves a change in capital structure (liquidation of a subsidiary) and has a material impact on financial results, but it is not a standard earnings release (ER) or a full interim/annual report (IR/10-K). It describes a specific corporate action with financial consequences, fitting best under Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if no better fit exists. Since it details a major change in asset valuation and corporate structure due to an internal transaction, 'CAP' (Capital/Financing Update) is the most appropriate fit as it relates to capital structure changes and significant financial adjustments, although 'RNS' is a strong secondary candidate for material non-standard announcements.
2023-12-21 Polish
Rozpoczęcie projektu opracowania i wdrożenia na rynek innowacyjnego wyrobu medycznego do stosowania w trudno gojących się ranach - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a short announcement (1906 characters) from PHARMENA S.A. referencing a previous report (Raport bieżący nr 14/2023) and detailing the initiation of a new project: developing an innovative medical device. It outlines the stages, budget (3 million PLN), timeline (3 years), and potential financing sources (own funds or EU grants). It explicitly states that the company will inform about subsequent stages via current reports in the ESPI system. Because this is a brief announcement detailing a significant business development and potential future financial impact, but is not a full financial report (like 10-K or IR), nor a specific announcement like a dividend or management change, it falls best under a general regulatory announcement. Given the context of reporting on strategic business developments that could impact the company's future, and since it doesn't fit the specific categories like CAP (financing activity is secondary to the project announcement) or LTR (it's not a legal proceeding), the most appropriate general category for a significant, non-standard regulatory update is RNS (Regulatory Filings/Miscellaneous). It is not an RPA because it is announcing a project, not the publication of a previously defined report.
2023-12-18 Polish
Pharmena_Raport za III kwartał 2023
Interim / Quarterly Report Classification · 100% confidence The document is a table of contents for a 'Śródroczny skrócony skonsolidowany raport kwartalny' (Interim condensed consolidated quarterly report) for the period ending September 30, 2023. It contains detailed sections on financial statements (balance sheet, income statement, cash flow, equity changes) and management commentary. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the Interim / Quarterly Report category. 9M 2023
2023-11-27 Polish
Ustalenie ostatecznej ceny zbycia zorganizowanej części przedsiębiorstwa - Content (PL)
M&A Activity Classification · 95% confidence The document is a formal announcement from the Management Board (Zarząd) of Pharmena S.A. in Polish. It refers to a previous report (raport bieżący nr 11/2023) concerning the sale of shares and a business unit. This specific report details the finalization of the sale price for a business unit (zorganizowanej części przedsiębiorstwa) and the payment terms. This transaction involves a significant change in assets/operations, which often relates to financing, capital structure, or major corporate actions. Since the document is a formal, current report detailing a specific corporate event (sale/disposal of a business unit leading to revenue recognition), it fits best under categories related to corporate actions or financing updates. It is not a standard 10-K, ER, or IR. Given the context of a sale/disposal of a business unit, it is most closely related to 'Capital/Financing Update' (CAP) as it directly impacts the company's financial structure and revenue realization from a major transaction. It is a specific corporate event announcement, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains substantive information about the final price and payment schedule.
2023-10-30 Polish
Udzielenie patentu w Europie - Content (PL)
Regulatory Filings Classification · 99% confidence The document text is a formal announcement by the Management Board (Zarząd) of PHARMENA S.A. stating that they received information about the granting of a patent (EP 3484475) by the European Patent Office concerning the use of 1-MNA. The text details the scope of the patent protection and explicitly states that this information may affect the valuation of the company's assets (patents and applications). This content relates to intellectual property rights and their impact on the company's value, which is a significant corporate event. It is not a standard financial report (10-K, IR, ER), a management change (MANG), or a director's trade (DIRS). Since it concerns a specific legal/IP development that impacts assets, it fits best under Legal Proceedings Report (LTR) if it were a lawsuit, but here it is a positive IP grant. Given the options, this type of announcement regarding significant intellectual property rights and their valuation impact is often categorized under Regulatory Filings (RNS) as a general material event disclosure, or potentially LTR if interpreted broadly as a legal status update, but RNS is the most appropriate general regulatory disclosure category for material, non-standard announcements not covered elsewhere. However, since it is a specific announcement about a newly granted patent, which is a form of corporate asset/legal status update, and it is not a standard financial report, RNS is the best fit as a general regulatory disclosure.
2023-09-15 Polish
Nowy obszar działalności Spółki - Content (PL)
Management Reports Classification · 99% confidence The document is a 'Raport bieżący' (Current Report) in Polish, announcing a strategic business expansion into developing and marketing an innovative medical device for hard-to-heal wounds. This announcement details future plans, potential financing sources (EU grants or own funds), and the expected timeline (3 years for trials/certification). This type of forward-looking strategic update, which is not a standard financial report (10-K, IR, ER) or a specific transaction like M&A or share dealing, fits best under a general regulatory announcement category. Given the options, it is a significant business update that doesn't fit the specific financial or governance codes. It is most appropriately classified as a general Regulatory Filing (RNS), as it is a mandatory disclosure of material information that doesn't match the other specific categories like CAP (financing update, though financing is mentioned, the core is strategy), LTR (not legal), or MDA (not a management discussion of past results). Since the document is short and reports a material event, RNS is the most suitable fallback.
2023-09-14 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.